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Background: Lower extremity percutaneous vascular interventions (LE PVIs) are generally performed to improve the quality of life (QoL) of patients 
with symptomatic peripheral arterial disease (PAD). We sought to evaluate and compare the baseline and 6 month post-intervention QoL in patients 
who underwent PVI of three arterial beds: aorto-iliac (AI), femoral-popliteal (FP), and below-the-knee (BTK).
Methods: QoL data were assessed at baseline and 6 months using the Peripheral Arterial Questionnaire (PAQ) for 1024 PVI patients in a 
multicenter, multidisciplinary regional consortium. Analysis of variance was employed to compare temporal change in QoL based on site of PVI.
Results: (See graph). At baseline, patients with AI interventions reported lower overall QoL and more physical limitation than patients with PVI 
of either the FP or BTK beds (p<0.05). At 6 months, patients with AI PVIs reported a better QoL, fewer physical limitations (p=0.039), better social 
functioning, and a more stable living experience than other patients (p<0.05). Finally, improvement over 6 months was greater for patients with AI 
PVIs in the areas of overall QoL, physical limitations, symptoms, social functioning and stability (p<0.05).
Conclusions: LE PVI for patients with symptomatic PAD is associated with significant improvement in QoL. While dramatic improvement was seen 
in all patient groups, patients with AI disease were more impaired at baseline, but achieved greater improvement compared with FP or BTK disease.
